Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?
Eyes are on the rollout of Lilly's new weight loss pill.
Read the full articleYou might also wanna read
Eli Lilly is reinventing the pharma business
The world’s largest drugmaker is betting big on preventive medicines—and learning from big tech
Novo gains head start on Lilly with European Commission approval of Wegovy pill
In Novo Nordisk and Eli Lilly’s competition to launch their respective GLP-1 obesity pills in the United States, the Danish ...
How new weight-loss drugs may offer hope for curbing addiction
Drugmakers are racing to develop ever newer versions of the GLP-1 drugs, and regulators around the world are approving them at an equally ra
CVS Health to restore Zepbound coverage and add Eli Lilly's new obesity pill to drug plans
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.
cnbc.com·1mo agoWeight-loss drug developers line up to tap lucrative market as competition heats up
HEALTH-OBESITY:Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up
STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect
A new startup is making a bold move in the world of obesity drug development: It’s not working with the GLP-1 target that has taken the worl
Comments
Sign in to join the conversation.
No comments yet. Be the first.